MOCTANIN
LOE Approachingmonoctanoin
NDAPERFUSION, BILIARYLIQUIDPriority Review
Approved
Oct 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MOCTANIN (monoctanoin) is a biliary perfusion liquid approved in 1985 for direct instillation into the biliary tree to dissolve gallstones. It is a medium-chain triglyceride that works by solubilizing cholesterol in gallstones, enabling non-surgical stone dissolution in select patients. This niche therapeutic addresses patients who are poor candidates for cholecystectomy.
LOE Approaching
With LOE approaching and minimal linked job openings, commercial team size is likely small or static, indicating a maintenance-mode portfolio product with limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MOCTANIN offers limited career advancement due to its niche indication, mature lifecycle stage, and minimal linked job postings. Roles are primarily focused on maintaining market presence and managing existing customer relationships rather than driving growth or innovation.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.